<div id="readability-page-1"><p>Bellevue Group AG trimmed its position in shares of  Penumbra, Inc. (NYSE:PEN - Free Report) by 14.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor  owned 174,050 shares of the company's stock after selling 30,467 shares during the period. Penumbra comprises  1.0% of Bellevue Group AG's investment portfolio, making the stock its 24th largest position. Bellevue Group AG owned 0.45% of Penumbra worth $44,666,000 at the end of the most recent reporting period.</p><ul><li>3 Mid-Cap Medical Stocks Outperforming the Market</li></ul><p>Several other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of  Penumbra by 5.0% during the second quarter. Vanguard Group Inc. now owns 3,860,655 shares of the company's stock worth $990,760,000 after acquiring an additional 185,306 shares in the last quarter.  Geode Capital Management LLC boosted its stake in shares of  Penumbra by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 706,404 shares of the company's stock valued at $181,314,000 after purchasing an additional 17,772 shares in the last quarter.  Invesco Ltd. grew its holdings in shares of  Penumbra by 1,139.3% during the 2nd quarter. Invesco Ltd. now owns 633,485 shares of the company's stock valued at $162,571,000 after purchasing an additional 582,369 shares during the last quarter.  Norges Bank purchased a new position in  Penumbra in the 2nd quarter worth $114,014,000.  Finally, AQR Capital Management LLC lifted its stake in  Penumbra by 139.4% in the second quarter. AQR Capital Management LLC now owns 330,990 shares of the company's stock worth $84,939,000 after purchasing an additional 192,734 shares during the last quarter. Hedge funds and other institutional investors own  88.88% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research analysts have recently issued reports on PEN shares. Needham &amp; Company LLC  reaffirmed a &#34;buy&#34; rating and set a $326.00 price objective on shares of Penumbra in a research note on Monday, October 27th. Truist Financial reduced their price target on Penumbra from $310.00 to $300.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, October 15th. Canaccord Genuity Group boosted their price objective on Penumbra from $350.00 to $355.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, November 6th. BTIG Research  reissued a &#34;buy&#34; rating and set a $320.00 price objective on shares of Penumbra in a research note on Monday, October 27th. Finally, Wells Fargo &amp; Company started coverage on shares of Penumbra in a report on Tuesday, November 18th. They issued an &#34;underweight&#34; rating on the stock. One investment analyst  has rated the stock with a Strong Buy rating, thirteen have assigned  a Buy rating, three have issued  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat, Penumbra  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $309.75.</p><ul><li>Are These Medical Device Makers Getting Ready To Rally? </li></ul><p><b>Check Out Our Latest Research Report on PEN</b></p><h2>Insider Buying and Selling</h2><p>In other news, Director Harpreet Grewal sold 186 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $248.61, for a total value of $46,241.46. Following the completion of the transaction, the director owned 8,702 shares of the company's stock, valued at approximately $2,163,404.22. This represents a 2.09% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director Arani Bose sold 7,500 shares of the firm's stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $290.56, for a total value of $2,179,200.00. Following the completion of the transaction, the director owned 282,761 shares of the company's stock, valued at approximately $82,159,036.16. The trade was a 2.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 19,744 shares of company stock valued at $5,755,174 over the last three months. Corporate insiders own  4.20% of the company's stock. </p><h2>Penumbra Price Performance</h2><p>Shares of Penumbra stock opened at $312.41 on Friday. The company has a market cap of $12.23 billion, a PE ratio of 74.74, a P/E/G ratio of 2.57 and a beta of 0.66. The business has a 50 day moving average of $269.05 and a 200 day moving average of $259.24. Penumbra, Inc. has a 52 week low of $221.26 and a 52 week high of $315.01. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. </p><p>Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The business had revenue of $354.69 million during the quarter, compared to analyst estimates of $340.77 million. During the same period in the prior year, the business earned $0.85 EPS. The company's revenue for the quarter was up 17.8% on a year-over-year basis.  As a group, equities research analysts forecast that  Penumbra, Inc. will post 3.67 earnings per share for the current year. </p><h2>About Penumbra</h2> (Free Report)<p>Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Penumbra</li><li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li><li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li><li>Where to Find Earnings Call Transcripts</li><li>The Best Holiday Present You Can Give Yourself? Costco Stock</li><li>What Makes a Stock a Good Dividend Stock?</li><li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Penumbra Right Now?</h2><p>Before you consider Penumbra, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.</p><p>While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bellevue Group AG reduced its stake in Penumbra, Inc. by 14.9% in Q2, selling 30,467 shares. Penumbra's stock is rated "Moderate Buy" with an average target price of $309.75. Insiders sold 19,744 shares worth $5.76 million recently. Penumbra's stock opened at $312.41, with a market cap of $12.23 billion and a PE ratio of 74.74.</p>

Bellevue Group AG Sells 30,467 Shares of Penumbra, Inc. $PEN